Dorsey Wright & Associates Sells 37,975 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dorsey Wright & Associates trimmed its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,887 shares of the company’s stock after selling 37,975 shares during the period. Dorsey Wright & Associates’ holdings in Teva Pharmaceutical Industries were worth $2,885,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TEVA. Schroder Investment Management Group raised its stake in shares of Teva Pharmaceutical Industries by 145.1% in the 4th quarter. Schroder Investment Management Group now owns 2,229,786 shares of the company’s stock valued at $49,769,000 after purchasing an additional 1,320,076 shares during the period. DnB Asset Management AS raised its position in Teva Pharmaceutical Industries by 13.3% in the 4th quarter. DnB Asset Management AS now owns 184,940 shares of the company’s stock valued at $4,076,000 after buying an additional 21,727 shares during the last quarter. Orion Portfolio Solutions LLC lifted its stake in Teva Pharmaceutical Industries by 11.9% in the 4th quarter. Orion Portfolio Solutions LLC now owns 12,302 shares of the company’s stock valued at $271,000 after acquiring an additional 1,310 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Teva Pharmaceutical Industries by 9.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 598,487 shares of the company’s stock worth $13,191,000 after acquiring an additional 52,938 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $38,550,000. 54.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

TEVA has been the subject of several recent research reports. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Bank of America decreased their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $15.06 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The stock’s 50 day moving average price is $17.21 and its two-hundred day moving average price is $18.12. The firm has a market capitalization of $17.07 billion, a price-to-earnings ratio of -10.38, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.